Pentetic acid occurs as a white crystalline solid and is almost
odorless.
Diethylenetriaminepentaacetic acid is a solid.
chelating agent, diagnostic aid
Diethylenetriaminepentaacetic acid is used as chelating agent and forms complexes with metal ions. It finds application as a magnetic resonance imaging (MRI) contrasting agent, since it improves the image by forming a complex with a gadolinium ion. It can also be used for treatment of radioactive materials such as plutonium, americium and other actinides. It is an active component of manganese and zinc fertilizers used in agrochemical industry. It acts as a color inhibitor and is used in the production of acrylon. It is also used in soaps as a water softener.
Diethylenetriaminepentaacetic Acid is a component of manganese and zinc fertilizers.
ChEBI: Pentetic acid is a pentacarboxylic acid. It has a role as a copper chelator. It is a conjugate acid of a pentetate(1-).
Pentetic acid is a pentaacetic acid triamine formed during the
preparation of the amino carboxylic acid and its salt.
Pharmaceutical Applications
Pentetic acid is mainly used as a chelating agent in the preparation
of imaging and contrast agents for radionuclide and magnetic
resonance imaging.It is also used as a carrier excipient for
neutron-capture isotopes in, for example, radiotherapy.Pentetic
acid–isotope complexes have also been considered as model active
substances in scintigraphic imaging studies.Pentetic acid has been
used to chelate metal ions to reduce formation of reactive oxygen
species during lyophilization.
Moderately toxic by
intraperitoneal route. When heated to
decomposition it emits toxic fumes of NOx.
Pentetic acid is used in intrathecal and intravenous injection
preparations. The pure form of pentetic acid is moderately toxic
by the intraperitoneal route.
LD50 (mouse, IP): 0.54 g/kg
LD50 (mouse, oral): 4.84 g/kg
The activity of pentetic acid as a chelating agent may cause
unwanted effects in formulations containing metal ions. The desired
chelate may be displaced by other ions from the formulation.
Crystallise DTPA from water. Dry under vacuum or at 110o. [Bielski & Thomas J Am Chem Soc 109 7761 1987, NMR: Wenzel et al. Anal Chem 54 615 1982, Beilstein 4 IV 2454.]
The activity of pentetic acid as a chelating agent may cause
unwanted effects in formulations containing metal ions. The desired
chelate may be displaced by other ions from the formulation.
Included in the FDA Inactive Ingredients Database (intrathecal and
intravenous injections). Included in intravenous and intra-articular
injections licensed in the UK.
